Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of YYD601 in NERD Patients
NCT03967886Phase 3Completed
- Sponsor
- Yooyoung Pharmaceutical
- Start
- Apr 2019
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of YYD601 in non-erosive reflux disease (NERD) (2 arms), sponsored by Yooyoung Pharmaceutical. Primary endpoints: Recovered percentage(%) of the symptom at 4 weeks, Change of the score about the symptom at 4 weeks and 3 more. Started Apr 2019; status: completed.
02
Drugs
YYD601
03
Conditions
non-erosive reflux disease (NERD)
Beyond the preview
Go deeper on NCT03967886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03967886.